Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

被引：0
|
作者：
Toshihiko Kaneda
Hiroshige Yoshioka
Motohiro Tamiya
Akihiro Tamiya
Akito Hata
Asukaka Okada
Takashi Niwa
Takayuki Shiroyama
Masaki Kanazu
Tadashi Ishida
Nobuyuki Katakami
机构：
[1] Kurashiki Central Hospital,Department of Respiratory Medicine
[2] Osaka Prefectural Medical Center for Respiratory and Allergic Diseases,Department of Thoracic Malignancy
[3] National Hospital Organization Kinki-chuo Chest Medical Center,Department of Internal Medicine
[4] Institute of Biomedical Research and Innovation,Division of Integrated Oncology
[5] Saiseikai Suita Hospital,Department of Respiratory Medicine
来源：
BMC Cancer | / 18卷
关键词：
Exon 19 deletion; L858R point mutation in exon 21; Non-squamous non-small cell lung cancer; Pemetrexed; Progression-free survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type
    Murakami, Shuji
    Saito, Haruhiro
    Kondo, Tetsuro
    Oshita, Fumihiro
    Yamada, Kouzo
    [J]. JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, 2019, 13 (02) : 131 - 138
  • [42] Review of the pemetrexed-cisplatin chemotherapy in non-squamous non-small cell lung cancer in Royal Shrewsbury Hospital
    Boon, C.
    Chatterjee, A.
    [J]. LUNG CANCER, 2013, 79 : S15 - S15
  • [43] Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
    Costa, D. B.
    Kobayashi, S.
    [J]. BRITISH JOURNAL OF CANCER, 2007, 96 (02) : 399 - 399
  • [44] Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer
    Rosell, Rafael
    Gonzalez-Cao, Maria
    [J]. LANCET, 2021, 397 (10274): : 557 - 559
  • [45] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
    Xiong, Liwen
    Lou, Yuqing
    Bai, Hao
    Li, Rong
    Xia, Jinjing
    Fang, Wentao
    Zhang, Jie
    Han-Zhang, Han
    Lizaso, Analyn
    Li, Bing
    Gu, Aiqin
    Han, Baohui
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [46] Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
    Minami, Seigo
    Kijima, Takashi
    [J]. LUNG CANCER-TARGETS AND THERAPY, 2015, 6 : 13 - 25
  • [47] Selective Targeting of the L858R Mutation (EGFR) in Non-Small Cell Lung Cancer: A Mechanism for Advancing Targeted Chemotherapy
    Arora, Rohan
    Krishnan, Venkat
    [J]. FRONTIERS IN ONCOLOGY, 2017, 7
  • [48] Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?
    D B Costa
    S Kobayashi
    [J]. British Journal of Cancer, 2007, 96 : 399 - 399
  • [49] Multicenter phase II study of cisplatin, pemetrexed, plus bevacizumab followed by maintenance pemetrexed plus bevacizumab for patients with advanced or recurrent non-squamous non-small cell lung cancer: MAP study
    Tsutani, Y.
    Miyata, Y.
    Masuda, T.
    Fujitaka, K.
    Doi, M.
    Awaya, Y.
    Kuyama, S.
    Kitaguchi, S.
    Ueda, K.
    Okada, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 137 - 137
  • [50] Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer
    Kaneda, Toshihiko
    Hata, Akito
    Tomioka, Hiromi
    Tanaka, Kosuke
    Kaji, Reiko
    Fujita, Shiro
    Tomii, Keisuke
    Katakami, Nobuyuki
    [J]. LUNG CANCER, 2014, 86 (02) : 213 - 218
12345